Key result
Q192R PON1 polymorphism shows no link to major cardiovascular events risk in clopidogrel-treated patients.
Why the study?
Clopidogrel responsiveness may be affected by the PON1 enzyme, motivating an assessment of the aggregated risk of MACEs associated with carrying the Q192R PON1 genetic variant in patients taking clopidogrel.
Does the Q192R PON1 genetic polymorphism affect the risk of MACEs in patients treated with clopidogrel?
Meta-Analysis (n=17,815)
Does the Q192R PON1 genetic polymorphism affect the risk of MACEs in patients treated with clopidogrel?
The Q192R PON1 genetic polymorphism does not significantly impact the risk of MACEs or bleeding events in patients treated with clopidogrel, suggesting routine genotyping for this variant may not be clinically useful.
Answers are grounded in this paper and cite their sources.
No association argues against routine Q192R PON1 genotyping with clopidogrel; challenges prior hypotheses of clinical relevance.
Background Clopidogrel’s responsiveness may be affected by the paraoxonase-1 (PON1) enzyme encoded by the Q192R PON1 genetic variant. We aimed to determine the aggregated risk of MACEs associated with carrying Q192R PON1 genetic variant in patients taking clopidogrel.Research design and methods Different databases were searched systematically for eligible studies, and risk ratio (RR) was measured using RevMan software where P <0.05 was set statistically significant.Results Nineteen studies were included consisting of 17,815 patients. It was found that patients carrying either homozygous or a combination of heterozygous and homozygous variants were not significantly associated with increased risk of MACEs compared to the non-carriers (QQ vs. RR: RR=0.99, 95% CI 0.69–1.42, P=0.96; QQ+QR vs RR; RR=1.05, 95% CI 0.82–1.35, P=0.70). The risk of MACEs was also not significantly different in other genetic model (QQ vs QR+RR) (RR=1.09, 95% CI 0.93–1.27, P=0.30). Further, bleeding events were not significantly different in different genetic models (QQ vs RR; RR=1.13, 95% CI 0.58–2.21, P=0.71; QQ+QR vs RR; RR=1.09, 95% CI 0.66–1.81, P=0.73; QQ vs QR+RR; RR=1.08, 95% CI 0.76–1.55, P=0.66).Conclusions The results suggest that the Q192R PON1 genetic polymorphism has no significant impact on the risk of MACEs or bleeding events in patients treated with clopidogrel.
No takes yet. Share an insight, caveat, or question.
Biswas et al. (2023) conducted a meta-analysis in Patients treated with clopidogrel (n=17,815). Q192R PON1 genetic variant (QQ or QQ+QR) vs. Non-carriers (RR or QR+RR) was evaluated on Major adverse cardiovascular events (MACEs) (RR 0.99, 95% CI 0.69-1.42, p=0.96). The Q192R PON1 genetic polymorphism was not associated with the risk of MACEs in patients treated with clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: